...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >The development and clinical evaluation of second-generation leishmaniasis vaccines.
【24h】

The development and clinical evaluation of second-generation leishmaniasis vaccines.

机译：第二代利什曼病疫苗的开发和临床评估。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Infection with Leishmania parasites results in a range of clinical manifestations and outcomes. Control of Leishmania parasite transmission is extremely difficult due to the large number of vectors and potential reservoirs, and none of the current treatments are ideal. Vaccination could be an effective strategy to provide sustained control. In this review, the current global situation with regard to leishmaniasis, the immunology of Leishmania infection and various efforts to identify second generation vaccine candidates are briefly discussed. The variety of clinical trials conducted using the only current second generation vaccine approved for clinical use, LEISH-F1+MPL-SE, are described. Given that epidemiological evidence suggests that reducing the canine reservoir also positively impacts human incidence, efforts at providing a vaccine for leishmaniasis in dogs are highlighted. Finally, potential refinements and surrogate markers that could expedite the introduction of a vaccine that can limit the severity and incidence of leishmaniasis are discussed.Digital Object Identifier http://dx.doi.org/10.1016/j.vaccine.2011.11.005
机译：感染利什曼原虫的寄生虫会导致一系列临床表现和结果。由于大量的病媒和潜在的宿主，控制利什曼原虫寄生虫的传播极为困难，目前的治疗方法都不理想。疫苗接种可能是提供持续控制的有效策略。在这篇综述中，简要讨论了关于利什曼病，利什曼原虫感染的免疫学以及鉴定第二代候选疫苗的各种努力的全球现状。描述了使用当前唯一批准用于临床的第二代疫苗LEISH-F1 + MPL-SE进行的各种临床试验。鉴于流行病学证据表明减少犬类水库也对人类发病率产生积极影响，因此着重于为狗提供利什曼病的疫苗。最后，讨论了可能加快疫苗开发进程的潜在改进和替代标记，这些疫苗可以限制利什曼病的严重性和发病率。数字对象标识符http://dx.doi.org/10.1016/j.vaccine.2011.11.005

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号